22 completed, 5 terminated, 4 unknown, 1 active not recruiting. 32 Phase 1, 11 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 32 | Completed 22, Terminated 5, Unknown 4, Active not recruiting 1 |
| Phase 2 | 11 | Completed 4, Unknown 4, Terminated 2, Active not recruiting 1 |
Follow Stage III Mantle Cell Lymphoma: new trials by email Literature Review of Stage III Mantle Cell Lymphoma trials Research Report on Stage III Mantle Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 anti-CD19/22-CAR vector-transduced T cells - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 30 | 2017-08-01 | 2019-04-17 |
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 anti-CD19/20-CAR vector-transduced T cells - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Completed | Chinese PLA General Hospital | 100 | 2017-04-01 | 2020-09-02 |
| Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine - HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Active not recruiting | AIDS Malignancy Consortium | 11 | 2016-06-23 | 2026-05-18 |
| Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma anti-CD19 CAR-T, Fludarabine, Cyclophosphamide - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Unknown | The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine | 20 | 2016-02-01 | 2017-03-16 |
| Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma CD19.CAR-T cells - Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Follicular Lymphoma | Phase 1 / Phase 2 | Unknown | Xinqiao Hospital of Chongqing | 20 | 2015-12-01 | 2019-02-27 |
| Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas lenalidomide, etoposide, prednisone - Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | University of Chicago | 55 | 2014-07-29 | 2026-03-11 |
| Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas brentuximab vedotin, rituximab, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Northwestern University | 20 | 2013-03-05 | 2021-09-01 |
| Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy anti-CD20-CAR vector-transduced autologous T cells, genetically engineered lymphocyte therapy - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 50 | 2013-01-01 | 2015-09-29 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant tetanus-CMV fusion peptide vaccine, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 | Completed | City of Hope Medical Center | 36 | 2012-10-29 | 2024-04-02 |
| RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors gamma-secretase/Notch signalling pathway inhibitor RO4929097, capecitabine, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2010-06-01 | 2014-11-07 |
| AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma Pharmacodynamic Studies, Fatigue Inventory, Pharmacogenomic studies - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Amir Mortazavi | 44 | 2010-05-04 | 2018-06-04 |
| CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy CART-19 - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 | Completed | University of Pennsylvania | 26 | 2010-03-17 | 2023-06-22 |
| Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma lenalidomide, rituximab, polymerase chain reaction - Adult Non-Hodgkin Lymphoma, Adult Grade III Lymphomatoid Granulomatosis | Phase 1 | Terminated | Case Comprehensive Cancer Center | 5 | 2010-01-01 | 2015-11-26 |
| Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery R-(-)-gossypol acetic acid, paclitaxel, carboplatin - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 36 | 2009-07-01 | 2013-01-10 |
| FAU in Treating Patients With Advanced Solid Tumors or Lymphoma 2'-F-ara-deoxyuridine, positron emission tomography, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 12 | 2009-07-01 | 2014-01-07 |
| Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery Dasatinib, Pharmacological Study - Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 80 | 2008-10-01 | 2015-07-02 |
| Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma vorinostat, rituximab, ifosfamide - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 / Phase 2 | Completed | University of Washington | 29 | 2007-12-01 | 2017-05-25 |
| Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction vorinostat, pharmacological study - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 15 | 2007-06-01 | 2014-02-24 |
| 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma gemcitabine hydrochloride, triapine - Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2006-06-01 | 2013-09-30 |
| PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma tanespimycin, belinostat, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 36 | 2006-05-01 | 2013-05-16 |
Showing 20 of 32. Sign in to see all of them.
Lymphoma, Follicular (32) · Lymphoma, Mantle-Cell (32) · Leukemia, Lymphocytic, Chronic, B-Cell (30) · Lymphoma, Large B-Cell, Diffuse (30) · Lymphoma, B-Cell, Marginal Zone (25) · Burkitt Lymphoma (24) · Lymphoma, Non-Hodgkin (23) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (22) · Lymphoma, Large-Cell, Immunoblastic (21) · Waldenstrom Macroglobulinemia (20) · Hodgkin Disease (19) · Lymphoma, Large-Cell, Anaplastic (17) · Lymphoma, T-Cell, Cutaneous (16) · Mycosis Fungoides (16) · Sezary Syndrome (16)
Hemic and Lymphatic Diseases (32) · Immune System Diseases (32) · Immunoproliferative Disorders (32) · Lymphatic Diseases (32) · Lymphoma (32) · Lymphoma, B-Cell (32) · Lymphoproliferative Disorders (32) · Neoplasms (32) · Neoplasms by Histologic Type (32) · Chronic Disease (30) · Disease Attributes (30) · Hematologic Diseases (30) · Leukemia (30) · Leukemia, B-Cell (30) · Leukemia, Lymphoid (30)
Rituximab (7) · Cyclophosphamide (3) · Etoposide (3) · Vorinostat (3) · fludarabine phosphate (3) · Bortezomib (2) · Carboplatin (2) · Cyclosporine (2) · Lenalidomide (2) · Mycophenolic Acid (2) · Peripheral Blood Stem Cell Transplantation (2) · Pharmacogenomic Testing (2) · belinostat (2) · tanespimycin (2) · 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (1)
National Cancer Institute (NCI) (17) · Chinese PLA General Hospital (3) · Fred Hutchinson Cancer Center (2) · AIDS Malignancy Consortium (1) · Amir Mortazavi (1) · Case Comprehensive Cancer Center (1) · City of Hope Medical Center (1) · Northwestern University (1) · The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine (1) · University of Chicago (1) · University of Pennsylvania (1) · University of Washington (1) · Xinqiao Hospital of Chongqing (1)
United States (26) · China (5) · Canada (2) · Germany (1) · Italy (1)
Adam Petrich, MD (1) · Ajay Gopal (1) · Amir Mortazavi, MD (1) · Antonius Miller (1) · Bo Zhu, M.D., Ph.D. (1) · Brenda Sandmaier (1) · Chandra Belani (1) · Charles Erlichman (1) · Colleen Delaney (1) · George Wilding (1) · John Byrd (1) · John Sarantopoulos (1) · Karen Yee (1) · Lihua Budde (1) · Mark Ratain (1)
PMID 34515338, PMID 25317870, PMID 25444722, PMID 26853648, PMID 26943915, PMID 28270022, PMID 29263894, PMID 30562587, PMID 31076448, PMID 31388792, PMID 31815579, PMID 32245502, PMID 32499241, PMID 33492438, PMID 40720747, PMID 41804087
U01CA062491 (3), U01CA076576 (3), U01CA062487 (2), U01CA069912 (2), U01CA099168 (2), U01CA132123 (2), N01CM62208 (1), P01CA018029 (1), P30CA014520 (1), P30CA014599 (1), P30CA015083 (1), P30CA015704 (1), P30CA016058 (1), P30CA022453 (1), P30CA047904 (1)